No description available.

[1] Four specimens of zoned tourmaline from granitic pegmatites are characterised in detail, each having unusual compositional and/or morphologic features: (1) a crystal from Black Rapids Glacier, Alaska, showing a central pink zone of elbaite mantled by a thin rim of green liddicoatite; (2) a large (~25 cm) slab of Madagascar liddicoatite cut along (001) showing complex patterns of oscillatory zoning; and (3) a wheatsheaf and (4) a mushroom elbaite from Mogok, Myanmar, both showing extensive bifurcation of fibrous crystals originating from a central core crystal, and showing pronounced discontinuous colour zoning. Crystal chemistry and crystal structure of these samples are characterised by SREF, EMPA, and 11B and 27Al MAS NMR and Mössbauer spectroscopies. For each sample, compositional change, as a function of crystal growth, is characterised by EMPA traverses, and the total chemical variation is reduced to a series of linear substitution mechanisms. Of particular interest are substitutions accommodating the variation in [4]B: (1) TB + YAl ↔ TSi + Y(Fe, Mn)2+, where transition metals are present, and (2) TB2 + YAl ↔ TSi2 + YLi, where transition metals are absent. Integration of all data sets delineates constraints on melt evolution and crystal growth mechanisms. [2] Uncertainty has surrounded the occurrence of [4]Al and [4]B at the T-site in tourmaline, because B is difficult to quantify by EMPA and Al is typically assigned to the octahedral Y- and Z-sites. Although both [4]Al and [4]B have been shown to occur in natural tourmalines, it is not currently known how common these substituents are. Using 11B and 27Al MAS NMR spectroscopy, the presence of [4]B and [4]Al is determined in fifty inclusion-free tourmalines of low transition-metal content with compositions corresponding to five different species. Chemical shifts of [4]B and [3]B in 11B spectra, and [4]Al and [6]Al in 27Al spectra, are well-resolved, allowing detection of very small (< ~0.1 apfu) amounts of T-site constituents. Results show that contents of 0.0 < [4]B, [4]Al < 0.5 apfu are common in tourmalines containing low amounts of paramagnetic species, and that all combinations of Si, Al and B occur in natural tourmalines.

[1] Four specimens of zoned tourmaline from granitic pegmatites are characterised in detail, each having unusual compositional and/or morphologic features: (1) a crystal from Black Rapids Glacier, Alaska, showing a central pink zone of elbaite mantled by a thin rim of green liddicoatite; (2) a large (~25 cm) slab of Madagascar liddicoatite cut along (001) showing complex patterns of oscillatory zoning; and (3) a wheatsheaf and (4) a mushroom elbaite from Mogok, Myanmar, both showing extensive bifurcation of fibrous crystals originating from a central core crystal, and showing pronounced discontinuous colour zoning. Crystal chemistry and crystal structure of these samples are characterised by SREF, EMPA, and 11B and 27Al MAS NMR and Mössbauer spectroscopies. For each sample, compositional change, as a function of crystal growth, is characterised by EMPA traverses, and the total chemical variation is reduced to a series of linear substitution mechanisms. Of particular interest are substitutions accommodating the variation in [4]B: (1) TB + YAl ↔ TSi + Y(Fe, Mn)2+, where transition metals are present, and (2) TB2 + YAl ↔ TSi2 + YLi, where transition metals are absent. Integration of all data sets delineates constraints on melt evolution and crystal growth mechanisms. [2] Uncertainty has surrounded the occurrence of [4]Al and [4]B at the T-site in tourmaline, because B is difficult to quantify by EMPA and Al is typically assigned to the octahedral Y- and Z-sites. Although both [4]Al and [4]B have been shown to occur in natural tourmalines, it is not currently known how common these substituents are. Using 11B and 27Al MAS NMR spectroscopy, the presence of [4]B and [4]Al is determined in fifty inclusion-free tourmalines of low transition-metal content with compositions corresponding to five different species. Chemical shifts of [4]B and [3]B in 11B spectra, and [4]Al and [6]Al in 27Al spectra, are well-resolved, allowing detection of very small (< ~0.1 apfu) amounts of T-site constituents. Results show that contents of 0.0 < [4]B, [4]Al < 0.5 apfu are common in tourmalines containing low amounts of paramagnetic species, and that all combinations of Si, Al and B occur in natural tourmalines.

No description available.

La Résonance Magnétique Nucléaire (RMN) à l’état solide avec rotation à l’angle magique (MAS) est une technique de choix pour l’étude de la structure et de la dynamique de molécules biologiques peu ou non solubles. Un grand nombre d’approches ont été développées pour la reconstitution de structures tridimensionelles à partir de mesures précises de proximités internucléaires, ainsi que pour la détection de mouvements moléculaires avec une résolution atomique sur des échelles de temps couvrant plusieurs ordres de grandeur. Malgré d’impressionnants progrès, les études par RMN MAS sont cependant loin d’être réalisées en routine. Les déterminations structurelles et de dynamique sont souvent démontrées sur des préparations microcristallines modèles, mais sont encore rares pour des systèmes plus complexes tels que les fibrilles amyloïdes non cristallines ou les protéines trans-membranaires insérées dans des bi- couches lipidiques. Mon travail a pour objectif d’étendre les possibilités de la RMN MAS pour l’étude de systèmes biomoléculaires complexes dans différents états d’agrégation. Pour cela, j’ai exploité les possibilités uniques offertes par les hauts champs magnétiques (fréquence de Larmor du 1H 700, 800 et 1000 MHz) combinés avec les sondes MAS de dernières générations capables d’atteindre des vitesses de rotations supérieures à 60 kHz. Ces conditions expérimentales per- mettent d’augmenter la sensibilité de la RMN MAS à l’aide de la détection 1H à haute résolution et d’enrichir la palette de paramètres RMN rapporteurs de la dynamique des protéines. La première partie de cette thèse décrit le développement de nouvelles stratégies pour l’attribution des résonances du squelette de protéines, pour l’élucidation de structures, et pour l’étude de la dynamique du squelette peptidique et des chaînes latérales. Les méthodes présentées réduisent significative- ment les besoins en termes de temps expérimental, de quantités d’échantillon et de marquage isotopique, et permettent d’analyser par RMN des systèmes de plus hauts poids moléculaire. La seconde partie décrit l’application de la RMN MAS avec détection en 1H pour l’évaluation du rôle de la dynamique des protéines dans des processus tels que la formation de fibrilles amyloïdes et le fonctionnement de protéines membranaires. Une première application est l’étude de la tendance de la β-2 microglobuline humaine à former des fibrilles amyloïdes. Une comparaison de la dynamique du squelette peptidique de la protéine sauvage et du mutant D76N dans leur forme cristalline, ainsi que la détermination de propriétés structurales de la forme fibrillaire m’ont permis d’identifier la présence de repliements pathologiques et de formuler des hypothèses sur le mécanisme de formation des fibrilles. Finalement, la dynamique locale et globale de protéines membranaires dans des bicouches lipidiques a été étudiée. En particulier, le mécanisme d’action d’un transporteur d’alkanes, AlkL, de P. putida a été examiné dans un environnement lipidique. La détermination de paramètres pour la dynamique rapide (ps-ns) et lente (μs-ms) du squelette peptidique de la protéine en présence ou en absence de substrat met en évidence des acheminements possibles pour le transfert de molécules vers la membrane et jette les bases pour une meilleure compréhension du processus. / Solid-state NMR with magic angle spinning (MAS) has emerged as a powerful technique for investigating structure and dynamics of insoluble or poorly soluble biomolecules. A number of approaches has been designed for reconstructing molecular structures from the accurate measurement of internuclear proximities, and for probing motions at atomic resolution over timescales spanning several orders of magnitude. Despite this impressive progress, however, MAS NMR studies are still far from routine. Complete determinations, which are often demonstrated on model microcrystalline preparations, are still rare when it comes to more complex systems such as non-crystalline amyloid fibrils or transmembrane proteins in lipid bilayers. My work aimed at extending the possibilities of MAS NMR for applications on complex biomolecular systems in different aggregation states. For this, I exploited the unique possibilities provided by high magnetic fields (700, 800 and 1000 MHz 1H Larmor frequency) in combination with the newest MAS probes capable of spinning rates exceeding 60 kHz. These experimental conditions al- low to boost the sensitivity of MAS NMR through 1H detection at high resolution and to enrich the palette of probes for protein dynamics. The first part of the thesis reports on my contribution to the development of new strategies for backbone resonance assignment, for structure elucidation, and for investigation of backbone and side-chain dynamics. These methodologies significantly reduce the requirements in terms of experimental time, sample quantities and isotopic labeling, and enlarge the molecular size of systems amenable to NMR analysis. The second part describes the application of 1H detected MAS NMR to evaluate the role of protein dynamics in problems such as amyloid fibril formation and membrane protein function. I first addressed the amyloid fibril formation propensity of human beta-2 microglobulin, the light chain of the major histocompatibility complex I. I performed comparative studies of backbone dynamics of the wild type protein as well as a D76N mutant in crystals, and determined some of the structural features of the fibrillar form. This allowed to identify the presence of pathological folding intermediates and to formulate hypotheses on the mechanism of fibrils formation. Finally, I studied the local and global dynamics of membrane proteins in lipid bilayers. In particular, I investigated the mechanism of action of the alkane trans- porter AlkL from P. putida in lipid bilayers. The measurement of parameters for fast (ps-ns) and slow (μs-ms) backbone dynamics of the protein in presence or in absence of a substrate highlights possible routes for molecular uptake and lays the basis for a more detailed mechanistic understanding of the process.

The study of quadrupolar nuclei using NMR spectroscopy in the solid state significantly increased in popularity from the end of the 20th century, with the introduction of specific methods to acquire spectra free from the effects of the quadrupolar interaction, that results in broadened lineshapes that cannot be completely removed by spinning the sample at the magic angle (MAS), unlike most of the other interactions present in the solid state. The first technique which allows, without any specific hardware, the removal of this broadening has been the Multiple-Quantum MQMAS experiment. The method quickly gained a popularity within the NMR community, with numerous successful applications published. However, the multiple-quantum filtration step in this experiment relies on severely limits sensitivity, restricting application to the most sensitive nuclei. Extending the applicability of MQMAS to less receptive nuclei requires the use of signal improvement techniques. There are multiple examples of such approaches in the literature, but most of these require additional optimisation that may be time-consuming, or simply impossible, on less receptive nuclei. This work introduces a novel signal improvement technique for MQMAS, called FAM-N. Its optimisation is solely based on density matrix simulations using SIMPSON, implying no additional experimental optimisation is required, while improving the signal in MQMAS spectra by equivalent or higher amounts than other common methods. In order to prove the applicability of this method on virtually any system, FAM-N has been investigated by simulation, and tested experimentally using a number of model samples, as well as samples known to be challenging to study by NMR. This work also explores other aspects of NMR spectroscopy on quadrupolar nuclei. Adiabatic inversion of the satellite populations can be performed to improve the central transition signal in static or MAS spectra. A range of methods has been tested and compared, with particular attention given to hyperbolic secant-shaped pulses, for which its performance have been described. Finally, cross-polarisation from a spin I = 1/2 nucleus to a quadrupolar nucleus has been investigated. After reviewing the theory for the static case, simulations have been performed under MAS in order to identify the conditions for efficient magnetisation transfer, with applications in spectral editing or for the combination with MQMAS.

La métabolomique a pour objet l’identification et la quantification de métabolites dans un échantillon biologique. Cette discipline s’inscrit dans une approche du vivant connue sous le terme de « biologie des systèmes ». La spectroscopie par résonance magnétique nucléaire haute résolution à l’angle magique (RMN HRMAS) est une méthode de choix pour l’obtention de ce type de profilage métabolique. L’épilepsie du lobe temporal (ELT) est une épilepsie focale fréquente associée le plus souvent à des pertes neuronales sélectives, une gliose réactionnelle et une plasticité cellulaire spécifique. Bien que restant débattue, une origine neurométabolique reste un axe de recherche majeur. A ce jour une caractérisation métabolomique des tissus épileptogènes par RMN HRMAS reste à effectuer. Notre travail a consisté dans un premier temps à caractériser, chez le rat, les effets des méthodes de prélèvement et de fixation sur le métabolome cérébral dans le cadre des acquisitions RMN HRMAS. Dans un second temps, nous avons travaillé sur le modèle animal lithium-pilocarpine d’ELT. Nous avons pu décrire le métabolome issu des données RMN 1H HRMAS de différentes structures cérébrales impliquéesdans l’épileptogénèse. Des analyses multivariées de type PLS-DA ont pu mettre en évidence des profils métaboliques pathologiques au sein du cortex entorhinal et de l’hippocampe. A l’aide de substrats marqués au carbone 13 ([1-13C]glucose et de [1,2-13C]acétate) nous avons étudié les voies métaboliques neuronales et gliales. Nos résultats suggèrent l’absence d’anomalies métaboliques au sein des astrocytes. Enfin dans un dernier temps, nous avons effectué des analyses RMN 1H HRMAS sur près de 200 échantillons cérébraux de patients atteints d’ELT. Une analyse multivariée a permis de distinguer les profils métaboliques des hippocampes sclérosés et non sclérosés. En revanche la construction de modèles sur la base d’hypothèses clinico métaboliques (durée de la maladie, fréquence de crises, antécédents de convulsions fébriles) n’a pas permis d’identifier de profils métaboliques spécifiques. L’ensemble de ces données suggère l’existence de profils métabolomiques distincts en fonction des caractéristiques neuropathologiques des patients atteints d’ELT. Notre travail confirme la nécessité d’une approche intégrée de type « biologie des systèmes » pour l’étude de l’ELT aussi bien chez l’homme que dans des modèles animaux. / Metabolomics relates to the identification and quantification of metabolites in biological samples. This discipline is part of an approach known under the term of "systems biology". High Resolution Nuclear Magnetic Resonance Spectroscopy at Magic Angle Spinning (HRMAS NMR) is a method for obtaining metabolic profiling in such sample. Temporal Lobe Epilepsy (TLE ) is a common focal epilepsy often associated with selective neuronal loss, reactive gliosis and specific cellular plasticity. A neurometabolic origin of this epilepsy is a major area of research. To date no characterization of human cerebral biopsy from TLE patients has been conducted using HRMAS NMR. In the present work we aimed first at characterizing, in rats, the effects of sampling methods and fixation on brain metabolome under HRMAS NMR acquisitions. In a second step, we studied the lithium-pilocarpine model of TLE. In this model, we could describe the metabolome from HRMAS 1H NMR data of different brain structures involved in epileptogenesis. Multivariate analysis could highlight pathological metabolic profiles in the entorhinal cortex and hippocampus. Using substrates labeled with carbon 13 ( [1 -13C ]-glucose and [1,2-13C ]-acetate) we studied neuronal and glial metabolic pathways. Our results suggest the absence of metabolic abnormalities in astrocytes metabolism as previously reported. Finally, we conducted HRMAS 1H NMR analysis in nearly 200 brain samples from TLEpatients. Multivariate analysis was able to distinguish metabolic profiles between sclerotic and non sclerotic hippocampi. However mutlivariate models based on clinico- metabolic assumptions (disease duration, frequency of seizures, history of febrile seizures ) did not identify specific metabolic profile. All these data suggest the existence of distinct metabolomic profile based on neuropathological features of patients with TLE. Our work confirm the need of an integrated approach such as " systems biology" for the study of TLE in humans as long as in animal models.

Background Prostate cancer (PCa) is the most frequently diagnosed malignant disease among adult males in the USA and the second leading cause of cancer deaths in men. Due to the lack of diagnostic tools that are able to differentiate highly malignant and aggressive cases from indolent tumors, overtreatment has become very common in the era of prostate specific antigen (PSA) screening. New diagnostic methods to determine biological status, malignancy, aggressiveness and extent of PCa are urgently needed. 1H High Resolution Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy (1H HRMAS MRS) can be used to establish PCa metabolomic profiles while preserving tissue architecture for subsequent histopathological analysis. Immunohistochemistry (IHC), as opposed to conventional histopathology methods, has the potential to provide objective, more accurate and quantitative knowledge of tissue pathology. This diagnostic- accuracy study sought to evaluate a novel approach to quantitatively identify metabolomic markers of PCa by exploring the potential of PCa immunomarkers to quantify metabolomic profiles established by 1H HRMAS MRS. Material and Methods 1H HRMAS MRS was performed on tissue samples of 51 prostate cancer patients using a 14.1 Tesla NMR spectrometer (BRUKER Biospin, Billerica, MA) with a rotor synchronized CPMG pulse sequence. Spectral intensities of 36 regions of interest were measured as integrals of curve fittings with Lorentzian-Gaussian line shapes. Immunohistochemistry (IHC) was carried out following the spectroscopy scan, using three prostate immunomarkers to identify cancerous and benign glands: P504S (Alpha-methylacyl-CoA-racemace), CK903 (high-molecular weight cytokeratin) and p63. The immunostaining quality following 1H HRMAS MRS was evaluated and compared to unscanned sections of the same sample, to verify the stability and accessibility of the proposed immunomarkers. IHC images were automatically and quantitatively evaluated, using a quantitative image analysis program (QIAP), to determine the percentage of cancerous and benign epithelia in the tissue cross- sections. The results of the program were validated by a correlation with the results of a quantitative IHC review and quantitative conventional histopathology analysis performed by an experienced pathologist. Ultimately, spectral intensities and the cancer epithelium percentage, obtained from quantitative immunohistochemistry, were correlated in order to validate PCa metabolomic markers identified by 1H HRMAS MRS. Patient outcomes and incidence of recurrence were determined by retrospective review of medical records five years after initial surgery. Categories of recurrence were correlated to spectral intensities to explore potential metabolomic markers of recurrence in the cohort. Results Immunostainings with P504S and CK903 showed excellent staining quality and accessibility following 1H HRMAS MRS, suggesting these markers to be suitable for the presented quantitative approach to determine metabolomics profiles of PCa. In contrast, the quality of p63 IHC was impaired after previously performed spectroscopy. IHC using the immunomarkers P504S and CK903 on adjacent slides was found to present a feasible quantitative diagnostic method to distinguish between benign and cancerous conditions in prostate tissue. The cancer epithelium percentage as determined by QIAP showed a significant correlation to the results of quantitative IHC analysis performed by a pathologist (p < 0.001), as well as to a quantitative conventional histopathology review (p = 0.001). The same was true for the benign epithelium percentage (p < 0.001 and p = 0.0183), validating the presented approach. Two metabolomic regions showed a significant correlation between relative spectral intensities and the cancer epithelium percentage as determined by QIAP: 3.22 ppm (p = 0.015) and 2.68 ppm (p = 0.0144). The metabolites corresponding to these regions, phosphocholine and citrate, could be identified as metabolomic markers of PCa in the present cohort. 45 patients were followed for more than 12 months. Of these, 97.8% were still alive five years after initial surgery. 11 patients (24.4%) experienced a recurrence during the follow- up time. The categories of recurrence showed a correlation to the spectral intensities of two regions, 2.33 – 2.3 ppm (p = 0.0403) and 1.28 ppm (p = 0.0144), corresponding to the metabolites phosphocreatine and lipids. Conclusion This study introduces a method that allows an observer-independent, quantitative analysis of IHC to help establish metabolomic profiles and identify metabolomic markers of PCa from spectral intensities obtained with 1H HRMAS NMR Spectroscopy. The immunomarkers P504S and CK903 have been found suitable IHC analysis following 1H HRMAS MRS. A prospective in vivo application of PCa metabolite profiles and metabolomic markers determined by the presented method could serve as highly sensitive, non- invasive diagnostic tool. This observer- independent, computer- automated, quantitative analysis could help to distinguish highly aggressive tumors from low-malignant conditions, avoid overtreatment and reduce risks and complications for cancer patients in the future. Further studies are needed to verify the identified PCa metabolomic markers and to establish clinical applicability.:Table of Contents Glossary 1 Introduction 1. 1 Prostate Cancer 1. 2 Detection of Prostate Cancer – State of the Art 1. 2. 1 Prostate- Specific Antigen Test and Digital Rectal Examination 1.2.2 Radiographic Methods in PCa Detection 1.2.3 Transrectal Core Biopsies and Histopathological Analysis 1.2.4 Histopathological Grading of Prostate Cancer: GLEASON Score 1.3 Challenges and Need for New Approaches in PCa Diagnostic Management 2 Scientific Background I: Nuclear Magnetic Resonance,1H HRMAS NMR Spectroscopy and Metabolomic Profiles 2.1 Nuclear Magnetic Resonance 2.1.1 Spin Precession 2.1.2 Magnetic Resonance 2.1.3 Chemical Shift and J- coupling 2.2 Nuclear Magnetic Resonance 2.2.1 Magic Angle Spinning and 1H HRMAS NMR Spectroscopy 2.2.2 MAS Spinning Rates and Spinning Side Bands 2. 3 Metabolomics, Metabolite Profiles and Clinical Utility 3 Scientific Background II: Immunohistochemistry of Prostate Cancer 4 Aims of the Study 5 Material and Methods 5.1 Prostate Tissue Samples and Patient Demographics 5.2 1H HRMAS NMR Spectroscopy 5.2.1 Sample Preparation 5.2.2 Spectroscopy Scan 5.2.3 Data Processing 5.3 Immunohistochemistry 5.3.1 Immunohistochemistry Material and Equipment 5.3.2. Immunohistochemistry Protocol 5. 3. 3 Prostate Immunomarker Stability after 1H HRMAS NMR Spectroscopy 5.3.4 Qualitative IHC Analysis 5. 3.5 Quantitative IHC Analysis 5.3.5.1 Quantitative IHC Slide Review 5.3.5.2 Computer-Automated Quantitative IHC Analysis 5.3 Quantitative Histopathology 5. 4 Identification of Prostate Cancer Metabolomic Markers 5. 5 Patient Outcomes and Recurrence Categories 5.6 Statistical Analysis 6 Results 6. 1 Patient demographics 6. 2 Spectroscopy Results 6. 3 Immunohistochemistry 6. 3. 1 Evaluation of Prostate Immunomarker Stability after 1H HRMAS MRS 6. 3. 2 Qualitative Immunohistochemistry 6. 4 Quantitative Immunohistochemistry 6. 4. 1 Quantitative IHC Slide Review 6. 4. 2 Computer-Automated Quantitative IHC Evaluation using QIAP 6. 5 Quantitative Histopathology 6. 6 Identification of Prostate Cancer Metabolomic Markers using QIAP 6. 7 Patient Outcomes and Recurrence 7 Discussion 8 Summary / Abstract 9 Zusammenfassung 10 References 11 Erklärung über die eigenständige Abfassung der Arbeit 12 Danksagung 13 Lebenslauf und Publikationsverzeichnis Appendix A.1 Immunostaining protocols A.2 Spectral Intensities Measured by 1H HRMAS MRS in 51 Samples A.3 Graphs for Correlations of Spectral Intensities and CaE% determined by QIAP in 34 Additional Regions of Interest / Einführung Prostatakrebs ist eine häufigsten Krebserkrankungen in den USA und die zweithäufigste malignom- assoziierte Todesursache männlicher Patienten weltweit. Seit der Einführung des Prostata- spezifischen Antigen (PSA)- Screeningtests wird diese Krebsart in früheren Stadien diagnostiziert und therapiert, wodurch die Mortalitätsrate in den letzten Jahren deutlich reduziert werden konnte. Da moderne diagnostische Methoden bislang jedoch nicht ausreichend in der Lage sind, suffizient zwischen hochmalignen und weniger aggressiven Varianten dieses bösartigen Krebsleidens zu unterscheiden, werden häufig auch Patienten aggressiv therapiert, deren niedriggradiges Prostatakarzinom keine klinische Relevanz gehabt hätte. Es besteht daher ein großes wissenschaftliches Interesse an der Entwicklung neuer diagnostischer Methoden zur akkuraten Bestimmung von biologischem Status, Malignität, Aggressivität und Ausmaß einer Prostatakrebserkrankung. \\\\\\\"1H High Resolution Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy\\\\\\\" (1H HRMAS MRS) ist eine vielversprechende diagnostische Methode, welche es ermöglicht, metabolomische Profile von Prostatakrebs zu erstellen, ohne die Gewebsstruktur der analysierten Proben zu zerstören. Durch anschließende histopathologische Begutachtung lassen sich die erstellten Metabolitprofile validieren und evaluieren. Im Gegensatz zu konventionellen histopathologischen Methoden können durch immunhistochemische Verfahren dabei objektivere, akkuratere und quantifizierbare histopathologische Erkenntnisse gewonnen werden. Die vorliegende Studie präsentiert einen neuentwickelten diagnostischen Ansatz zur quantitativen Bestimmung von metabolomischen Markern von Prostatakrebs, basierend auf der Durchführung von 1H HRMAS NMR Spektroskopie und quantitativer Immunhistochemie. Material und Methoden Einundfünfzig Gewebsproben von Prostatakrebspatienten wurden mittels 1H HRMAS MRS an einem 14.1 T BRUKER NMR Spektrometer unter Einsatz einer CPMG-Pulssequenz untersucht. Spektrale Intensitäten in 36 Metabolitregionen wurden gemessen. Anschließend wurden die analysierten Gewebeproben mit drei Immunfärbemarkern für sowohl malignes (P504S, Alpha-methylacyl-CoA-racemase) als auch benignes (CK903, High-molecular weight cytokeratin, und p63) Prostatagewebe angefärbt und quantitativ mit Hilfe eines Bildanalyseprogramms (QIAP) ausgewertet. Die Anwendbarkeit und Auswertbarkeit der genannten Immunomarker nach Spektroskopie wurde evaluiert und mit der Färbungsqualität von nicht- gescannten Schnitten verglichen. Die Resultate der automatischen Auswertung durch QIAP konnten durch einen erfahrenen Pathologen in einer quantitativen Analyse der Immunfärbungen sowie konventioneller histologischer Färbungen derselben Gewebsproben validiert werden. Die spektralen Intensitäten aus den Messungen mit 1H HRMAS MRS wurden mit den korrespondierenden Ergebnissen der quantitativen Auswertung der Immunfärbungen korreliert, um metabolomische Marker von Prostatakrebs zu identifizieren. Der klinische Verlauf und die Rezidivrate der Patienten wurden 5 Jahre nach der initialen Prostatektomie retrospektiv bestimmt. Rezidivkategorien wurden erstellt und mit den bestimmten spektralen Intensitäten korreliert, um metabolomische Marker für das Auftreten von Prostatakrebsrezidiven zu identifizieren. Ergebnisse Die Immunfärbungen mit P504S und CK903 zeigten exzellente Qualität und Auswertbarkeit nach vorheriger 1H HRMAS MRS. Beide Marker eigneten sich zur Durchführung von quantitativer Immunhistochemie an spektroskopierten Gewebeproben. Im Gegensatz dazu war die Qualität der Immunfärbungen mit p63 nach Spektroskopie vermindert. Quantitative Immunfärbungen unter Einsatz der Immunmarker P504S und CK903 stellten eine praktikable diagnostische Methode dar, um zwischen malignen und benignem Prostatagewebe zu unterscheiden. Der Anteil von bösartig verändertem Prostatagewebe, bestimmt durch QIAP, korrelierte signifikant mit den Ergebnissen der quantitativen Analyse der Immunfärbungen durch den Pathologen (p < 0.001), sowie mit der quantitativen Auswertung der konventionellen histopathologischen Färbung (p = 0.001). Ebenso ließ sich die Bestimmung des Anteils von benignem Gewebe mit QIAP zu den Ergebnissen der pathologischen Analyse korrelieren (p < 0.001 und p = 0.0183). Für zwei metabolomische Regionen konnte ein signifikante Korrelation zwischen relativen spektralen Intensitäten, bestimmt mit 1H HRMAS NMR Spektroskopie, und dem Anteil von malignem Epithelium in derselben Gewebeprobe, ermittelt durch QIAP, festgestellt werden: 3.22 ppm (p = 0.015) und 2.68 ppm (p = 0.0144). Die zu diesen Regionen korrespondierenden Metaboliten, Phosphocholin und Zitrat, konnten als potentielle metabolomische Marker für Prostatakrebs identifiziert werden. Die retrospektiven Analyse der klinischen Daten der Patienten fünf Jahre nach Prostatektomie ergab eine Überlebensrate von 97.8%. Elf dieser Patienten (24.4%) erlitten ein Rezidiv ihrer Erkrankung. Die bestimmten Rezidivkategorien korrelierten signifikant mit zwei metabolomischen Regionen (2.33 – 2.3 ppm, p = 0.0403 und 1.28 ppm, p = 0.0144), welche zu den Metaboliten Phosphokreatin und Lipiden korrespondierten. Schlussfolgerung Die vorliegende Studie präsentiert einen diagnostischen Ansatz zur objektiven und quantitativen Bestimmung metabolomischer Marker von Prostatakrebs unter Verwendung von 1H HRMAS MRS und Immunhistochemie. P504S und CK903 eignen sich als Immunmarker für quantitative Immunfärbungen nach vorheriger Durchführung von 1H HRMAS MRS. Die Metaboliten Phosphocholin und Zitrat konnten in der vorliegenden Patientenkohorte als potentielle metabolomische Marker für Prostatakrebs identifiziert werden. Eine mögliche in vivo Anwendung der gefundenen metabolomischen Marker könnte als hochsensitives, objektives und nicht- invasives diagnostisches Werkzeug der Prostatakrebsdiagnostik dienen. Der vorliegende untersucherunabhängige, automatisierte und quantitative diagnostischer Ansatz hat das Potential, zwischen hochmalignen und weniger aggressiven Krebsfällen zu unterscheiden und somit unnötige Risiken und Komplikationen für Prostatakrebspatienten zu reduzieren. Weitere Untersuchungen sind notwendig, um die identifizierten metabolomischen Marker zu verifizieren und eine klinische Anwendung zu etablieren.:Table of Contents Glossary 1 Introduction 1. 1 Prostate Cancer 1. 2 Detection of Prostate Cancer – State of the Art 1. 2. 1 Prostate- Specific Antigen Test and Digital Rectal Examination 1.2.2 Radiographic Methods in PCa Detection 1.2.3 Transrectal Core Biopsies and Histopathological Analysis 1.2.4 Histopathological Grading of Prostate Cancer: GLEASON Score 1.3 Challenges and Need for New Approaches in PCa Diagnostic Management 2 Scientific Background I: Nuclear Magnetic Resonance,1H HRMAS NMR Spectroscopy and Metabolomic Profiles 2.1 Nuclear Magnetic Resonance 2.1.1 Spin Precession 2.1.2 Magnetic Resonance 2.1.3 Chemical Shift and J- coupling 2.2 Nuclear Magnetic Resonance 2.2.1 Magic Angle Spinning and 1H HRMAS NMR Spectroscopy 2.2.2 MAS Spinning Rates and Spinning Side Bands 2. 3 Metabolomics, Metabolite Profiles and Clinical Utility 3 Scientific Background II: Immunohistochemistry of Prostate Cancer 4 Aims of the Study 5 Material and Methods 5.1 Prostate Tissue Samples and Patient Demographics 5.2 1H HRMAS NMR Spectroscopy 5.2.1 Sample Preparation 5.2.2 Spectroscopy Scan 5.2.3 Data Processing 5.3 Immunohistochemistry 5.3.1 Immunohistochemistry Material and Equipment 5.3.2. Immunohistochemistry Protocol 5. 3. 3 Prostate Immunomarker Stability after 1H HRMAS NMR Spectroscopy 5.3.4 Qualitative IHC Analysis 5. 3.5 Quantitative IHC Analysis 5.3.5.1 Quantitative IHC Slide Review 5.3.5.2 Computer-Automated Quantitative IHC Analysis 5.3 Quantitative Histopathology 5. 4 Identification of Prostate Cancer Metabolomic Markers 5. 5 Patient Outcomes and Recurrence Categories 5.6 Statistical Analysis 6 Results 6. 1 Patient demographics 6. 2 Spectroscopy Results 6. 3 Immunohistochemistry 6. 3. 1 Evaluation of Prostate Immunomarker Stability after 1H HRMAS MRS 6. 3. 2 Qualitative Immunohistochemistry 6. 4 Quantitative Immunohistochemistry 6. 4. 1 Quantitative IHC Slide Review 6. 4. 2 Computer-Automated Quantitative IHC Evaluation using QIAP 6. 5 Quantitative Histopathology 6. 6 Identification of Prostate Cancer Metabolomic Markers using QIAP 6. 7 Patient Outcomes and Recurrence 7 Discussion 8 Summary / Abstract 9 Zusammenfassung 10 References 11 Erklärung über die eigenständige Abfassung der Arbeit 12 Danksagung 13 Lebenslauf und Publikationsverzeichnis Appendix A.1 Immunostaining protocols A.2 Spectral Intensities Measured by 1H HRMAS MRS in 51 Samples A.3 Graphs for Correlations of Spectral Intensities and CaE% determined by QIAP in 34 Additional Regions of Interest

No description available.

No description available.